Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
Pharma News, 2024
China NMPA approves Dizal’s golidocitinib for PTCL treatment
The National Medical Products Administration (NMPA) of China has approved Dizal’s golidocitinib for adults with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL)...
Biotest wins FDA approval for plasma protein therapy
The US Food and Drug Administration (FDA) approved Biotest’s Yimmugo for the treatment of primary antibody deficiencies. Biotest, a subsidiary of Grifols, announced that the US FDA granted a...
Pyros wins FDA approval for ready-to-use infantile spasm treatment
The US Food and Drug Administration (FDA) has signed off on a ready-to-use formulation of vigabatrin developed by Pryos Pharmaceuticals for infantile spasms, marking the first approval for a n...
Smartphone stroke detection breakthrough announced by Australian team
A new technology that allows smartphones to identify strokes far quicker than existing methods has been developed by researchers in Australia.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
AstraZeneca‘s Imfinzi (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for treating adults with primary advanced o...
Berberine Could Treat Eczema-Exacerbated Staphylococcus aureus Infections
Eczema, a skin inflammatory disease that causes dry, itchy and inflamed skin, affects millions worldwide.
Apple Watch can detect symptoms of Parkinson’s disease, study reveals
Smartwatches can detect symptoms of Parkinson’s and give scientists a better understanding of how to treat the disease, according to a new study.
Bristol Myers Squibb’s Augtyro granted expanded FDA approval for solid tumours
Bristol Myers Squibb’s Augtyro (repotrectinib) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat neurotrophic tyrosine receptor kinase (...
AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn
AbbVie and FutureGen Biopharmaceutical have announced a licence agreement worth $1.7bn to develop a pre-clinical therapy for inflammatory bowel disease (IBD).
FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
The US Food and Drug Administration (FDA) has granted approval for AstraZeneca‘s Farxiga (dapagliflozin) for the treatment of paediatric patients aged 10 years and above with type-2 ...
Santa Ana Bio secures $168m for inflammatory disease treatments
Since its inception in 2022, Santa Ana has progressed three programmes, with clinical trials expected to begin in 2025.
Merck KGaA invests in Life Science business facility in Germany
German science and technology company Merck KGaA has announced a €62m ($66.6m) investment to construct a new quality control facility for its Life Science business at its Darmstadt headquart...
25
26
27
28
29
30
31
32
33
